Compare ATOM & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATOM | MOLN |
|---|---|---|
| Founded | 2001 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.7M | 170.5M |
| IPO Year | 2016 | 2021 |
| Metric | ATOM | MOLN |
|---|---|---|
| Price | $4.14 | $3.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $10.36 |
| AVG Volume (30 Days) | ★ 377.7K | 1.7K |
| Earning Date | 10-27-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.41 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $62,000.00 | N/A |
| Revenue This Year | $361.54 | N/A |
| Revenue Next Year | $233.33 | $450.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.89 | $3.53 |
| 52 Week High | $12.37 | $5.36 |
| Indicator | ATOM | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 45.29 | 42.29 |
| Support Level | $4.16 | $3.79 |
| Resistance Level | $4.49 | $4.39 |
| Average True Range (ATR) | 0.22 | 0.16 |
| MACD | 0.05 | -0.05 |
| Stochastic Oscillator | 35.36 | 6.19 |
Atomera Inc is engaged in the business of developing, commercializing, and licensing proprietary processes and technologies for the semiconductor industry. The company's technology, named Mears Silicon Technology, or MST, is a thin film of re-engineered silicon, typically 100 to 300 angstroms (or approximately 20 to 60 silicon atomic unit cells) thick. MST can be applied as a transistor channel enhancement to CMOS-type transistors, the majority of widely used in the semiconductor industry. The company's silicon technology can be used for applications like Analog, DRAM, logic, processors, and SRAM. Geographically, it generates maximum revenue from North America.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.